首页 | 本学科首页   官方微博 | 高级检索  
     


Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer
Authors:Jamie Wagner D.O.   Judy C. Boughey M.D.   Betsy Garrett P.A-C.   Gildy Babiera M.D.   Henry Kuerer M.D.   Funda Meric-Bernstam M.D.   Eva Singletary M.D.   Kelly K. Hunt M.D.   Lavinia P. Middleton M.D.  Isabelle Bedrosian M.D.  
Affiliation:aDepartment of Surgical Oncology, The University of Texas; MD, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Abstract:

Background

Optimal surgical management of patients with invasive lobular carcinoma (ILC) who undergo neoadjuvant chemotherapy (NAC) is unknown. We evaluated optimal margin distance and local recurrence (LR) rates for these patients.

Methods

Ninety-three (30%) of 311 patients with ILC received NAC. We examined margin status, residual disease after re-excision, and clinical outcomes.

Results

Margin positivity rates after the final operative procedure were similar between the NAC and surgery-first group (P > .05). The proportion of patients, stratified by margin status, who were taken back for re-excision was not different between the 2 groups, and, similarly, there were no differences in frequency of residual disease (all P > .05). At a median follow-up of 3.1 years, 1 patient in the NAC group and 2 in the surgery-first group developed LR (P = 1.0).

Conclusions

Patients with ILC who have undergone NAC and have margins >1 mm have a low probability of residual disease and LR.
Keywords:Breast   Lobular cancer   Margins   Neoadjuvant chemotherapy   Local recurrence
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号